NASDAQ:OPRX OptimizeRx (OPRX) Stock Price, News & Analysis $13.55 +0.43 (+3.28%) As of 07/3/2025 03:16 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About OptimizeRx Stock (NASDAQ:OPRX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get OptimizeRx alerts:Sign Up Key Stats Today's Range$13.00▼$13.4750-Day Range$8.66▼$15.4452-Week Range$3.78▼$15.71Volume78,613 shsAverage Volume301,355 shsMarket Capitalization$250.68 millionP/E RatioN/ADividend YieldN/APrice Target$10.81Consensus RatingModerate Buy Company Overview OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events. The company was founded in 2006 and is based in Waltham, Massachusetts. Read More OptimizeRx Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks31st Percentile Overall ScoreOPRX MarketRank™: OptimizeRx scored higher than 31% of companies evaluated by MarketBeat, and ranked 1504th out of 1,998 stocks in the computer and technology sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.4 / 5Analyst RatingModerate Buy Consensus RatingOptimizeRx has received a consensus rating of Moderate Buy. The company's average rating score is 2.73, and is based on 8 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageOptimizeRx has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about OptimizeRx's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for OptimizeRx are expected to grow in the coming year, from ($0.33) to ($0.29) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of OptimizeRx is -16.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of OptimizeRx is -16.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioOptimizeRx has a PEG Ratio of 4.37. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioOptimizeRx has a P/B Ratio of 2.13. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about OptimizeRx's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.37% of the float of OptimizeRx has been sold short.Short Interest Ratio / Days to CoverOptimizeRx has a short interest ratio ("days to cover") of 5.4.Change versus previous monthShort interest in OptimizeRx has recently increased by 1.95%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOptimizeRx does not currently pay a dividend.Dividend GrowthOptimizeRx does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted9.37% of the float of OptimizeRx has been sold short.Short Interest Ratio / Days to CoverOptimizeRx has a short interest ratio ("days to cover") of 5.4.Change versus previous monthShort interest in OptimizeRx has recently increased by 1.95%, indicating that investor sentiment is decreasing. News and Social Media3.3 / 5News Sentiment1.01 News SentimentOptimizeRx has a news sentiment score of 1.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Computer and Technology companies.News Coverage This WeekMarketBeat has tracked 2 news articles for OptimizeRx this week, compared to 2 articles on an average week.Search Interest15 people have searched for OPRX on MarketBeat in the last 30 days. This is an increase of 1,400% compared to the previous 30 days.MarketBeat Follows1 people have added OptimizeRx to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, OptimizeRx insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.60% of the stock of OptimizeRx is held by insiders.Percentage Held by Institutions76.47% of the stock of OptimizeRx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about OptimizeRx's insider trading history. Receive OPRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for OptimizeRx and its competitors with MarketBeat's FREE daily newsletter. Email Address OPRX Stock News HeadlinesOptimizeRx Corp. (NASDAQ:OPRX) Receives $10.81 Consensus Price Target from BrokeragesJune 30, 2025 | americanbankingnews.comOptimizeRx Corporation Appoints CEO Steve Silvestro to Board of DirectorsJune 24, 2025 | globenewswire.comThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.July 4 at 2:00 AM | Paradigm Press (Ad)Calculating The Fair Value Of OptimizeRx Corporation (NASDAQ:OPRX)June 18, 2025 | finance.yahoo.comSimulmedia & OptimizeRx partner to bring Micro-Neighborhood® targeting to TV & streamingJune 18, 2025 | msn.comSimulmedia and OptimizeRx Announce Partnership from the Cannes LionsJune 18, 2025 | businesswire.comOptimizeRx to Participate in Upcoming Investor ConferencesMay 16, 2025 | globenewswire.comOptimizeRx Corporation (NASDAQ:OPRX) Q1 2025 Earnings Call TranscriptMay 13, 2025 | msn.comSee More Headlines OPRX Stock Analysis - Frequently Asked Questions How have OPRX shares performed this year? OptimizeRx's stock was trading at $4.86 at the beginning of 2025. Since then, OPRX stock has increased by 178.8% and is now trading at $13.55. How were OptimizeRx's earnings last quarter? OptimizeRx Corp. (NASDAQ:OPRX) released its earnings results on Monday, May, 12th. The company reported $0.08 earnings per share for the quarter, topping analysts' consensus estimates of ($0.11) by $0.19. The business earned $21.93 million during the quarter, compared to analysts' expectations of $18.69 million. OptimizeRx had a negative trailing twelve-month return on equity of 0.29% and a negative net margin of 16.33%. Read the conference call transcript. How do I buy shares of OptimizeRx? Shares of OPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of OptimizeRx own? Based on aggregate information from My MarketBeat watchlists, some other companies that OptimizeRx investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Tesla (TSLA), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Intel (INTC). Company Calendar Last Earnings5/12/2025Today7/04/2025Next Earnings (Estimated)8/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorComputer and Technology Industry COMP - SOFTWARE Sub-IndustryBusiness Services Current SymbolNASDAQ:OPRX CIK1448431 Webwww.optimizerx.com Phone(248) 651-6568Fax248-453-5529Employees100Year FoundedN/APrice Target and Rating Average Stock Price Target$10.81 High Stock Price Target$16.00 Low Stock Price Target$5.00 Potential Upside/Downside-20.2%Consensus RatingModerate Buy Rating Score (0-4)2.73 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)($0.84) Trailing P/E RatioN/A Forward P/E RatioN/A P/E Growth4.37Net Income-$18.66 million Net Margins-16.33% Pretax Margin-17.08% Return on Equity-0.29% Return on Assets-0.20% Debt Debt-to-Equity Ratio0.25 Current Ratio2.82 Quick Ratio2.82 Sales & Book Value Annual Sales$92.13 million Price / Sales2.72 Cash FlowN/A Price / Cash FlowN/A Book Value$6.35 per share Price / Book2.13Miscellaneous Outstanding Shares18,500,000Free Float17,459,000Market Cap$250.68 million OptionableOptionable Beta1.34 Social Links Beginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:OPRX) was last updated on 7/4/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored“E.I.”- The biggest prediction of my career?One expert predicts that E.I. could see over 200,000% growth... But you need to move fast...Behind the Markets | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OptimizeRx Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share OptimizeRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.